[Topical corticosteroids versus topical inhibitors of calcineurin].
Topical corticosteroids (TCC) have significantly shaped dermatological therapy for five decades. A few months ago the TCC were joined by competition, the topical inhibitors of calcineurin (TIC), wrongly termed topical immunomodulators. The present paper reviews the pharmacological effects and clinical efficacy of TIC, compares the risks, benefits and costs of those two groups of topical drugs and develops a position on the use of TIC. While TIC have ushered in a new era of topical anti-inflammatory therapy, the age of TCC is far from over.
Niedner
R
R
Klinik für Dermatologie, Klinikum Ernst von Bergmann gGmbH, Potsdam. rniedner@klinikumevb.de
D000208:Acute Disease; D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D065095:Calcineurin Inhibitors; D003524:Cyclosporins / Q000008:administration & dosage / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy; D004485:Eczema / Q000188:drug therapy; D005148:Facial Dermatoses / Q000188:drug therapy; D005938:Glucocorticoids; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D009450:Neurodermatitis / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D017511:Pyoderma Gangrenosum / Q000188:drug therapy; D012307:Risk Factors; D012871:Skin Diseases / Q000188:drug therapy*; D016559:Tacrolimus / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D065095:Calcineurin Inhibitors; D003524:Cyclosporins; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016559:Tacrolimus